A breast cancer survivor shares the discovery of a new kidney mass and details how she will be a smarter, more assertive ...

RASolute 302 showed daraxonrasib reduced mortality risk by 60% versus chemotherapy in previously treated metastatic PDAC, with median OS 13.2 versus 6.7 months. OPTIMA found Prosigna-defined low-risk ...

Dual PD-L1 and VEGF-A blockade with pumitamig plus chemotherapy yielded a 70% overall response rate and 100% disease control in evaluable first-line advanced NSCLC without actionable alterations.

Iza-bren improved survival and delayed disease progression versus chemotherapy in previously treated metastatic ...

Genotype-informed surveillance should pair colonoscopy with upper endoscopy when MLH1/MSH2 mutations or family history ...

Adding Opdivo (nivolumab) and Yervoy (ipilimumab) to chemotherapy did not improve how long patients with HER2-negative ...

Indications include newly diagnosed chronic-phase Ph+ CML and chronic/accelerated-phase disease after resistance or intolerance to prior therapy, including imatinib. Concomitant use with PPIs and ...

Randomized data support structured post-adjuvant exercise as a disease-modifying survivorship strategy, improving disease-free survival and overall survival compared with education-only control.

ASCO 2026: Telephone-based weight loss significantly improves physical function and mental health in patients with breast cancer patients who are overweight or obese. For many women diagnosed with ...

Male breast cancer remains underrecognized; cultural feminization of the disease contributes to embarrassment, isolation, and delayed care-seeking, leading to more advanced stage at diagnosis.

GLP-1 RA use was also tied to lower rates of immune-related side effects, caused by the immune system becoming overactive as a result of immunotherapy treatment. Patients taking GLP-1 drugs showed ...